There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX) and Mustang Bio (MBIO) with bullish sentiments.
Zogenix (ZGNX)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix today and set a price target of $55.00. The company’s shares closed last Tuesday at $19.68, close to its 52-week low of $16.65.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -3.9% and a 39.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zogenix with a $43.60 average price target.
See today’s analyst top recommended stocks >>
Mustang Bio (MBIO)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Mustang Bio today and set a price target of $13.00. The company’s shares closed last Tuesday at $4.35.
According to TipRanks.com, Mamtani is a top 100 analyst with an average return of 45.3% and a 63.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mustang Bio with a $11.20 average price target, a 157.5% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
